Cardiovascular Diseases
Argo Biopharma Announces First Patient Dosed in Phase 2b Trial of siRNA Therapeutic BW-20829 for Elevated Lp(a)
Argo Biopharma; BW-20829; Phase 2b trial; siRNA; Lp(a); Novartis; cardiovascular disease
Bayer and Vanderbilt University Medical Center Announce Five-Year Collaboration to Advance Cardiovascular and Kidney Disease Treatments
Bayer; Vanderbilt University Medical Center; cardiovascular diseases; kidney diseases; collaboration; precision medicine; BioVU
Corsera Health Launches with $50M Funding for Preventive Cardiovascular RNAi Program Advancing to Clinic
Corsera Health; cardiovascular disease; RNAi medicine; preventive program; clinic trials; funding; $50M
Cereno Scientific Secures SEK 100m in Directed Share Issue and SEK 350m Loan Financing, Targeting Milestones by Q4 2027
Cereno Scientific; SEK 100 million; Directed share issue; SEK 350 million; Loan financing; Q4 2027 milestones; HDAC inhibitor portfolio; Pulmonary arterial hypertension; Clinical development; Rare cardiovascular diseases
Merck Reports Pivotal PCSK9 Pill Data in Race to Beat AstraZeneca to Market
Merck; PCSK9 inhibitor; enlicitide; oral cholesterol pill; AstraZeneca; CORALreef trial; LDL-C reduction; AHA 2025; FDA approval; cardiovascular disease
Amgen Builds Case for Repatha to Prevent Heart Disease With Landmark Late-Stage Data
Amgen; Repatha; VESALIUS-CV trial; primary prevention; cardiovascular disease; PCSK9 inhibitor; LDL-C; FDA approval; major adverse cardiovascular events; heart attack; stroke
Novartis Acquires Tourmaline Bio for $1.4B to Bolster Cardiovascular Pipeline with Promising Phase 2 Drug
Novartis; Tourmaline Bio; acquisition; $1.4 billion; pacibekitug; cardiovascular disease; anti-inflammatory; IL-6 antibody; ASCVD; phase 2 trial; C-reactive protein; chronic kidney disease
Novartis and ProFound Therapeutics Forge $750M-Per-Target Cardiovascular Pact
Novartis; ProFound Therapeutics; cardiovascular disease; biotech partnership; drug discovery; proteomics; biobucks; flagship pioneering; pharmaceutical milestones
Eli Lilly Pays $1B Upfront to Acquire Verve Therapeutics, Expanding Cardiovascular Gene Editing Portfolio
Eli Lilly; Verve Therapeutics; gene editing; cardiovascular disease; acquisition; PCSK9; VERVE-102; biotech; heart disease
CRISPR Therapeutics Partners with Sirius for siRNA Therapies, Expanding Beyond Gene Editing
CRISPR Therapeutics; Sirius Therapeutics; siRNA; gene editing; SRSD107; cardiovascular diseases; thrombotic disease; biotech partnerships; Factor XI; anticoagulant therapies